Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in B-cell Lymphoma and CLL
NCT00290472Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Primary endpoints: Objective Overall Response Rate at 6 years, Duration of Response at 6 years and 1 more. Started Mar 2004; status: completed.
02
Drugs
temsirolimus
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00290472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290472.